Skip to Content

Baseline Patient Characteristics May Predict Psoriasis Course

TUESDAY, April 27, 2021 -- Patient characteristics at onset can help to estimate the long-term course of psoriasis with good discriminatory power, according to a study published online April 14 in JAMA Dermatology.

Axel Svedbom, from the Karolinska Institutet in Stockholm, and colleagues sought to describe the clinical course of psoriasis and identify possible indicators of long-term outcomes among a noninterventional cohort of patients enrolled between 2001 and 2005 and followed for 10 years. The analysis included 721 patients (≥15 years) with recent-onset psoriasis (<12 months duration).

The researchers found that the cumulative incidence of severe psoriasis at 12 years from enrollment was 21 percent. At follow-up, 77 of 389 patients with plaque onset (20 percent) and 56 of 116 with guttate onset (48 percent) had minimal disease activity without treatment, and 24 percent overall had psoriatic arthritis. The cumulative incidence of severe disease in patients with plaque phenotype, above-median disease activity, and scalp lesions was 52 percent versus 11 percent in patients with below-median disease activity at inclusion. Nearly six in 10 patients with peripheral enthesitis (59 percent) had psoriatic arthritis after 10 years versus 12 percent without initial joint pain. A severe disease course was also associated with smoking (hazard ratio, 1.70) and activating genes in the interleukin-23 pathway (odds ratio, 1.55). Early initiation of systemic therapy was associated with a lower risk for severe disease at 10 years versus later initiation of systemic therapy (odds ratio, 0.24).

"In the light of the persistent nontreatment and undertreatment of both psoriasis and psoriatic arthritis, the identified subgroups with elevated risk for severe skin disease and psoriatic arthritis merit close follow-up or specialist referrals to facilitate timely and appropriate intervention," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Bimekizumab Tops Secukinumab for Plaque Psoriasis

MONDAY, April 26, 2021 -- For patients with moderate-to-severe plaque psoriasis, bimekizumab is noninferior and superior to secukinumab and adalimumab, according to two studies...

Psoriasis Incidence in the United States Remains Steady

FRIDAY, April 23, 2021 -- Psoriasis incidence in the United States is steady, but increases with age and is higher among Whites, according to a study published in the April issue...

Psoriasis Linked to Higher Risk for Thyroid Disease

MONDAY, March 29, 2021 -- Psoriasis is associated with an increased risk for thyroid disease among U.S. adults, according to research published online March 16 in the Journal of...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.